Here are three stocks with buy rank and strong income characteristics for investors to consider today, January 7: Primo ...

Truist raised the firm’s price target on Fresenius Medical (FMS) to $25 from $23 and keeps a Hold rating on the shares as ...

Fresenius Medical Care (NYSE:FMS – Free Report) had its price target lifted by Truist Financial from $23.00 to $25.00 in a research note published on Monday,Benzinga reports. Truist Financial ...

StockNews.com initiated coverage on shares of Fresenius Medical Care (NYSE:FMS – Free Report) in a report released on Friday morning. The brokerage issued a strong-buy rating on the stock. Several ...

Fresenius Medical Care AG & Co KGaA is a Germany-based holding and kidney dialysis company, operating in the fields of dialysis products and dialysis services. Its dialysis business is vertically ...

Fresenius is a strong buy with a 60% Return on Revenue potential in the next 3 years, driven by earnings growth and strategic ...

German stocks are up marginally in cautious trade Friday morning as investors await U.S. non-farm payroll for some clarity about the ...

Formycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® Otulfi ® approved by Health Canada for both subcutaneous and intravenous ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

OtulfiTM received a Health Canada Notice of Compliance (NOC) approval on December 30th for both subcutaneous and intravenous formulationsWith this approval, Fresenius Kabi Canada's immunology ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Regulatory ApprovalFormycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® 08.01.2025 / 14:30 CET/CESTThe issuer is solely ...